Remission and recovery in lurasidone-treated patients with bipolar depression: post-hoc analysis of a 6-week, placebo-controlled trial followed by a 6-month extension

被引：0
|
作者：
Loebel, A. [1 ]
Siu, C. [2 ]
Rajagopalan, K. [3 ]
Pikalov, A. [4 ]
Cucchiaro, J. [5 ]
Ketter, T. [6 ]
机构：
[1] Sunovion Pharmaceut Inc, Ft Lee, NJ USA
[2] COS Consulting, Data Sci & Analyt, Montreal, PQ, Canada
[3] Sunovion Pharmaceut Inc, Hlth Econ & Outcomes Res, Marlborough, MA USA
[4] Sunovion Pharmaceut Inc, Clin Dev & Med Affairs, Ft Lee, NJ USA
[5] Sunovion Pharmaceut Inc, Clin Operat, Ft Lee, NJ USA
[6] Stanford Univ, Psychiat & Behav Sci, Stanford, CA 94305 USA
来源：
BIPOLAR DISORDERS | 2015年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [31] Analysis of relapses in mixed episode patients treated with aripiprazole: Post-hoc analysis of a 26-week, double-blind, placebo-controlled trial
    Ostacher, Michael
    Nierenberg, Andrew
    Eudicone, James
    Pikalov, Andrei
    Forbes, Andrew
    Marcus, Ronald
    Vester-Blokland, Estelle
    Carlson, Berit
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S223 - S224
  • [32] The Efficacy and Safety of Lurasidone in Adolescent Patients With Schizophrenia: A 6-Week, Double-Blind, Placebo-Controlled, Multicenter Study
    Correll, Christoph U.
    Goldman, Robert
    Silva, Robert
    Cucchiaro, Josephine
    Deng, Ling
    Loebel, Antony
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S597 - S598
  • [33] Frequency, correlates and outcomes of Benzodiazepine use during Cariprazine treatment: A pooled post-hoc analysis from four 6-week, placebo-controlled trials in patients with an acute exacerbation of schizophrenia
    Correll, Christoph U.
    Csehi, Reka
    Acsai, Karoly
    Barabassy, Agota
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2025, 94 : 76 - 83
  • [34] Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension
    Goldberg, Joseph F.
    Ng-Mak, Daisy
    Siu, Cynthia
    Chuang, Chien-Chia
    Rajagopalan, Krithika
    Loebel, Antony
    CNS SPECTRUMS, 2017, 22 (02) : 220 - 227
  • [35] Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Nosaka, Tadashi
    Higuchi, Teruhiko
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (07) : 227 - 235
  • [36] Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Nosaka, Tadashi
    Higuchi, Teruhiko
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, : 227 - 235
  • [37] Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial
    Lichtenstein, G. R.
    Gordon, G. L.
    Zakko, S.
    Murthy, U.
    Sedghi, S.
    Pruitt, R.
    Merchant, K.
    Shaw, A.
    Bortey, E.
    Forbes, W. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (08) : 990 - 999
  • [38] Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial
    Bruyere, Olivier
    Honvo, Germain
    Vidovic, Eduard
    Cortet, Bernard
    BIOMOLECULES, 2021, 11 (10)
  • [39] Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
    Calisti, F.
    Costamagna, I.
    Hsu, J.
    Tocco, M.
    Pikalov, A.
    Goldman, R.
    EUROPEAN PSYCHIATRY, 2021, 64 : S166 - S166
  • [40] Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
    Preeya J. Patel
    Christian Weidenfeller
    Andrew P. Jones
    Jens Nilsson
    Jay Hsu
    Neurology and Therapy, 2021, 10 : 121 - 147
12345